Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Quarterly results
Director departure
Appointed director
CorMedix Inc. (CRMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/28/2021 GN CorMedix Inc. to Participate at the 7th Annual Truist Securities Life Sciences Summit
04/07/2021 GN CorMedix Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference
03/23/2021 GN CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update on March 30
03/15/2021 GN CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program
03/11/2021 GN CorMedix Inc. Announces Contract Extension of Liz Masson-Hurlburt as Executive Vice President and Head of Clinical Operations
03/08/2021 GN CorMedix Inc. to Host Regulatory Update Conference Call
03/01/2021 GN CorMedix Receives Complete Response Letter From FDA for DefenCath™ Catheter Lock Solution
01/21/2021 GN CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange
11/18/2020 GN CorMedix Inc. Announces FDA Decision That Advisory Committee Meeting for New Drug Application for Defencath is Not Needed
10/08/2020 GN CorMedix to Participate in BIO Investor Forum Digital
09/17/2020 GN CorMedix Appoints Paulo Costa to its Board of Directors
07/28/2020 GN CorMedix Announces Pricing of $20M Public Offering of Common Stock
07/08/2020 GN CorMedix Inc. Reports Submission of Defencath™ New Drug Application
05/11/2020 GN CorMedix Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
05/11/2020 GN CorMedix Inc. Announces Appointment of Chief Financial Officer
04/23/2020 GN CorMedix Inc. Announces Contract Extension of Jack Armstrong as Executive Vice President and Head of Technical Operations
04/22/2020 GN CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program
03/06/2020 GN CorMedix Inc. to Report Fourth Quarter 2019 Financial Results and Provide a Corporate Update on March 16
11/06/2019 GN CorMedix Inc. Announces a Change to its Senior Leadership
09/26/2019 GN CorMedix Inc. to Present at the Cantor 2019 Global Healthcare Conference
09/26/2019 GN CorMedix Inc. Announces Exercises of Outstanding Warrants
09/03/2019 GN CorMedix Inc. to Present at the H.C. Wainwright 21st Annual Global Investment Conference
08/14/2019 GN CorMedix Inc. Announces Exchange Agreement With Its Largest Investor
08/13/2019 GN CorMedix Inc. Reports Second Quarter and Six Month 2019 Financial Results and Provides Business Update
07/17/2019 GN CorMedix Presents at FDA Public Meeting on the Limited Population Pathway for Antibacterial and Antifungal Drugs
07/09/2019 GN CorMedix Receives Encouraging FDA Feedback on Neutrolin® LOCK-IT-100 Data
07/08/2019 GN CorMedix Announces Publication of Taurolidine Pre-Clinical Oncology Data in “Investigational New Drugs” Journal
06/10/2019 GN CorMedix Inc. to Ring NYSE Closing Bell on Monday, June 10
05/16/2019 GN CorMedix Inc. to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
05/13/2019 GN CorMedix Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
05/06/2019 GN CorMedix Inc. to Report First Quarter 2019 Financial Results and Provide a Corporate Update on May 13
04/22/2019 GN CorMedix Announces Online Pre-Clinical Abstract at the Upcoming Annual Meeting of American Society of Clinical Oncology
04/17/2019 GN CorMedix Completes Sale of $5.4 Million of NOL Tax Benefits Through New Jersey Economic Development Authority Program
04/10/2019 GN Report: Exploring Fundamental Drivers Behind Allergan plc, Alamo Group, CorMedix, Foot Locker, Methode Electronics, and Motorcar Parts of America — New Horizons, Emerging Trends, and Upcoming Developments
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy